| Ai-Media Technologies Limited (AIM) ORDINARY FULLY PAID |
Industrials |
$51 |
Notice of Annual General Meeting/Proxy Form
|
26 Aug 2025 9:35AM |
$0.560 |
$0.245 |
fallen by
56.25%
|
|
| Estrella Resources Limited (ESR) ORDINARY FULLY PAID |
Materials |
$64 |
ESR extends milestone timeline in key limestone partnership
|
26 Aug 2025 9:34AM |
$0.032 |
$0.029 |
fallen by
9.38%
|
|
ESR - Price-sensitive ASX Announcement
Full Release
Key Points
- Estrella Resources Limited (ESR) has announced an extension of the milestone timeline for its limestone partnership with Carbine Resources Limited.
- The extension relates to the Option and Joint Venture Agreement between ESR and Carbine over the Spargoville Project, specifically in relation to the exploration and development of limestone deposits.
- The new milestone date extends the timeframe in which Carbine may complete its required feasibility studies and earn a 51% interest in the Spargoville Limestone Project.
- The extension was made to allow Carbine additional time to complete due diligence and feasibility activities due to delays encountered in the project assessment.
- All other terms and conditions of the initial agreement between ESR and Carbine remain unchanged.
- ESR believes the partnership remains strategically important for the development of the Spargoville Limestone Project and for the company's overall growth strategy.
- The company will provide further updates to shareholders as material developments occur regarding the partnership and the progress of the limestone project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$63 |
Appendix 4E and 2025 Annual Report
|
26 Aug 2025 9:34AM |
$0.150 |
$0.085 |
fallen by
43.33%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurizon Therapeutics Limited (NUZ) released its Appendix 4E and 2025 annual report covering the year ended 31 December 2025.
- The company focuses on the development of therapies for neurological and neuropsychiatric disorders.
- Key clinical and research milestones are detailed, including updates on lead drug candidates and ongoing trials.
- Financial results include income statement, balance sheet, and cash flow statement with accompanying notes.
- The directors’ report provides governance, risk management, and strategic outlook information.
- Discussion of research and development expenditure and progress on the clinical pipeline.
- Auditor’s statement and independent auditor’s report are included, confirming compliance and transparency.
- Corporate governance disclosures detail the company’s regulatory adherence and board practices.
- The report outlines the company’s commitment to sustainability, compliance, and shareholder engagement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PolarX Limited (PXX) ORDINARY FULLY PAID |
Materials |
$55 |
Trading Halt
|
26 Aug 2025 9:34AM |
$0.018 |
$0.020 |
risen by
11.11%
|
|
PXX - Price-sensitive ASX Announcement
Full Release
Key Points
- PolarX Limited (ASX:PXX) has requested a trading halt on its securities.
- The trading halt was effective from 20 June 2024.
- The halt is pending the release of an announcement to the market.
- Trading will resume at the earlier of normal trading on 24 June 2024 or the release of the announcement.
- The request was made under ASX Listing Rule 17.1.
- The trading halt is intended to ensure orderly management of the market.
- The Board of PolarX Limited approved the request.
- The announcement was authorised by Managing Director, Mr. Frazer Tabeart.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lake Resources NL (LKE) ORDINARY FULLY PAID |
Materials |
$229 |
Amendment to Kachi Phase One DFS Addendum Presentation
|
26 Aug 2025 9:33AM |
$0.032 |
$0.099 |
risen by
209.38%
|
|
LKE - Price-sensitive ASX Announcement
Full Release
Key Points
- Amendment to the Kachi Phase One DFS Addendum Presentation released by Lake Resources NL.
- Updated development schedule and revised capital/operating cost estimates for the Kachi Lithium Brine Project in Argentina.
- Incorporation of independent expert feedback and technical improvements.
- Optimized project design for improved sustainability and response to lithium market conditions.
- Key changes include adjusted production timelines and updated project financials (NPV and IRR).
- Continued stakeholder engagement, including local communities and regulators.
- Emphasis on environmental and social responsibility in project execution.
- Commitment to advancing the Kachi project using direct lithium extraction technology.
- Focus on project transparency, governance, and long-term value creation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$3,624 |
Statement of Changes in Beneficial Ownership
|
26 Aug 2025 9:33AM |
$122.290 |
$98.730 |
fallen by
19.27%
|
|
| Integral Diagnostics Limited (IDX) ORDINARY FULLY PAID |
Health Care |
$832 |
Dividend/Distribution - IDX
|
26 Aug 2025 9:33AM |
$2.720 |
$2.230 |
fallen by
18.01%
|
|
| Austral Gold Limited (AGD) ORDINARY FULLY PAID |
Materials |
$107 |
Austral Gold Announces Workplace Fatality at Guanaco Plant
|
26 Aug 2025 9:33AM |
$0.045 |
$0.160 |
risen by
255.56%
|
|
| Patagonia Lithium Ltd (PL3) ORDINARY FULLY PAID |
Materials |
$34 |
Results of Entitlement Offer
|
26 Aug 2025 9:32AM |
$0.038 |
$0.165 |
risen by
334.21%
|
|
| SKS Technologies Group Limited (SKS) ORDINARY FULLY PAID |
Industrials |
$796 |
Dividend/Distribution - SKS
|
26 Aug 2025 9:32AM |
$2.680 |
$6.900 |
risen by
157.46%
|
|
| Lowell Resources Fund (LRT) ORDINARY UNITS FULLY PAID |
Financials |
$93 |
LRT NAV Estimate - 22 August 2025
|
26 Aug 2025 9:32AM |
$1.550 |
$2.240 |
risen by
44.52%
|
|
| SKS Technologies Group Limited (SKS) ORDINARY FULLY PAID |
Industrials |
$796 |
Full Year Statutory Accounts
|
26 Aug 2025 9:32AM |
$2.680 |
$6.900 |
risen by
157.46%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$741 |
Application for quotation of securities - DJW
|
26 Aug 2025 9:32AM |
$3.150 |
$2.820 |
fallen by
10.48%
|
|
| Kip McGrath Education Centres Limited (KME) ORDINARY FULLY PAID |
Consumer Discretionary |
$32 |
Notification of buy-back - KME
|
26 Aug 2025 9:31AM |
$0.605 |
$0.575 |
fallen by
4.96%
|
|
| Decidr AI Industries Ltd (DAI) ORDINARY FULLY PAID |
Consumer Staple |
$201 |
$3.9M Options Underwriting Agreement Executed
|
26 Aug 2025 9:31AM |
$0.650 |
$0.625 |
fallen by
3.85%
|
|
DAI - Price-sensitive ASX Announcement
Full Release
Key Points
- Decidr AI Industries Ltd has executed a $3.9 million options underwriting agreement.
- The agreement underwrites the exercise of listed DAI options expiring 30 June 2024 at $0.08 per option.
- Significant shareholders and new investors have committed to the underwriting, ensuring capital certainty.
- Funds will be used to support AI-driven solution deployment, strategic opportunities, and corporate growth.
- The initiative strengthens DAI’s financial position and supports its ongoing technological innovation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ingenia Communities Group (INA) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,663 |
FY25 Property Portfolio
|
26 Aug 2025 9:31AM |
$5.960 |
$4.080 |
fallen by
31.54%
|
|
| SKS Technologies Group Limited (SKS) ORDINARY FULLY PAID |
Industrials |
$796 |
Preliminary Final Report
|
26 Aug 2025 9:31AM |
$2.680 |
$6.900 |
risen by
157.46%
|
|
SKS - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased to $82.9 million for FY23.
- Net loss after tax of $7.4 million, impacted by a non-cash impairment of goodwill and restructuring costs.
- Operating cash flows improved year on year.
- No final dividend declared for FY23.
- Strategic realignment undertaken to improve profitability.
- Company is focused on AV, electrical, and communications markets.
- Project pipeline remains strong with significant opportunities in core sectors.
- Risks include economic conditions, project delays, and competitive pressures.
- Corporate governance and risk management practices reaffirmed.
- Outlook anticipates further growth and efficiency improvements in FY24.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bryah Resources Limited (BYH) ORDINARY FULLY PAID |
Materials |
$6 |
Golden Pike Gold and Antimony Project Update
|
26 Aug 2025 9:30AM |
$0.005 |
$0.004 |
fallen by
20%
|
|
| Ingenia Communities Group (INA) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,663 |
FY25 Results Presentation
|
26 Aug 2025 9:30AM |
$5.960 |
$4.080 |
fallen by
31.54%
|
|
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$223 |
Proposed issue of securities - VTM
|
26 Aug 2025 9:29AM |
$1.580 |
$1.700 |
risen by
7.59%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$722 |
Fund Payment Notice June 2025
|
26 Aug 2025 9:29AM |
$3.020 |
$3.450 |
risen by
14.24%
|
|
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$223 |
Proposed issue of securities - VTM
|
26 Aug 2025 9:29AM |
$1.580 |
$1.700 |
risen by
7.59%
|
|
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$223 |
$11.5M INSTO PLACEMENT TO TARGET ULTRA-HIGH HREO ZONES
|
26 Aug 2025 9:29AM |
$1.580 |
$1.700 |
risen by
7.59%
|
|
VTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Victory Metals Limited (VTM) announced a successful institutional placement (Insto Placement) to raise A$11.5 million.
- The placement aims to advance exploration and drilling activities, particularly focusing on ultra-high Heavy Rare Earth Oxide (HREO) zones at the North Stanmore Project.
- The funds will be used to expand the drilling campaign to better define and potentially increase resources in high-grade HREO zones.
- Institutional and sophisticated investors showed strong support for the placement, with demand exceeding the amount raised.
- The placement will be completed in two tranches, subject to shareholder approval for the second tranche.
- VTM intends to use the raised capital for further exploration, drilling, assay work, metallurgical studies, and development activities.
- The North Stanmore Project is located in Western Australia and is considered highly prospective for ionic clay-hosted rare earth elements (REEs).
- The company’s primary objective is to develop a significant REE resource with a focus on elements critical for high-tech and clean energy applications.
- The announcement highlights the strategic importance of Australian-based supply of critical minerals to global markets.
- VTM is committed to advancing the North Stanmore Project towards resource expansion and development, with the goal of establishing a globally significant critical minerals project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Calix Limited (CXL) ORDINARY FULLY PAID |
Materials |
$127 |
Calix FY25 investor presentation
|
26 Aug 2025 9:29AM |
$0.465 |
$0.590 |
risen by
26.88%
|
|
CXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Calix Limited’s CXL technology is central to its offering, allowing industrial decarbonization through CO2 capture and utilization.
- The FY25 investor presentation covers financial performance, strategic goals, and growth outlook for the upcoming year.
- Calix is advancing commercialization with a growing project pipeline and new licensing and partnership agreements globally.
- Primary application areas for CXL include cement, lime, and lithium processing, with additional opportunities in water treatment and other sectors.
- The company targets substantial revenue growth, improved operating margins, and increased technology adoption in FY25.
- Calix’s strategy includes global expansion, scaling commercial projects, and leveraging intellectual property.
- Environmental, social, and governance (ESG) considerations are integral to Calix’s operations and growth plans.
- The presentation highlights Calix’s role in supporting the global transition to a net zero emissions economy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Integral Diagnostics Limited (IDX) ORDINARY FULLY PAID |
Health Care |
$832 |
FY25 Investor Presentation
|
26 Aug 2025 9:29AM |
$2.720 |
$2.230 |
fallen by
18.01%
|
|
IDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Integral Diagnostics Limited is a leading provider of diagnostic imaging services in Australia and New Zealand.
- The FY25 Investor Presentation reviews the company's FY24 financial results, including revenue growth and EBITDA performance.
- IDX highlights operational improvements and ongoing efficiency initiatives to drive profitability.
- The company outlines its technology and digital transformation efforts to enhance service delivery and clinical outcomes.
- Expansion strategies include targeted investments, network growth, and potential acquisitions.
- IDX discusses its response to healthcare policy changes and market dynamics impacting the diagnostic imaging sector.
- The presentation emphasizes a focus on quality, patient care, and clinical leadership.
- Future priorities involve operational excellence, innovation, and disciplined capital management.
- IDX provides financial guidance for FY25 and reiterates its commitment to delivering shareholder value.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
